Trading Companies and Distributors

DEXPO

DEXPO released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 244.32 M, actual EPS CNY -0.02

DEXPO FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

DEXPO released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 601.24 M, actual EPS CNY 0.2002

DEXPO released FY2025 annual earnings on April 23 After-Market (BJT), actual revenue CNY 1.626 B (forecast CNY 1.717 B), actual EPS CNY 0.45 (forecast CNY 0.4)

DEXPO to Release FY2025 Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 1.717 B, EPS CNY 0.4

DEXPO released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 471.33 M, actual EPS CNY 0.1655

DEXPO released FY2025 9 Months Earnings on October 27 After-Market (BJT), actual revenue CNY 1.025 B, actual EPS CNY 0.2706

DEXPO to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

DEXPO released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 321.74 M, actual EPS CNY 0.135

DEXPO released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 553.39 M, actual EPS CNY 0.08

DEXPO FY2025 Semi-Annual Earnings Release on August 30, 2025, BJT

Taiping Researcher Wang Zhan Gives 'Buy' Rating to Lunsheng Stock

Pacific Researcher Wang Zhan Gives Buy Rating to Lansen Shares

Pacific Researcher Gives Lan Sheng Share 'Buy' Rating

Lansheng Co. Granted Authorization to Dispose of Up to RMB 800 Million in Financial Assets

Lansheng Co. Q1 2025 Earnings Report Shows Net Profit Decline

DEXPO released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 231.65 M, actual EPS CNY -0.03

Wang Zhan Comments on Lan Sheng Shares 2024 Annual Report: Accelerated Layout of Exhibition Industry Full Chain

DEXPO FY2025 Q1 Earnings Release Scheduled for April 29 After-Market BJT

Lansheng Co. Exceeded Voluntary Earnings Targets in 2024

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

MorningStar

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

600826

600158

300651

The sports concept fluctuated and weakened during the session, with Huayang Racing down nearly 10%. Jinling Sports, DEXPO, CSI, Yeguangming, and Kangbite all fell over 4%

Zhitong

Jinling Sport

The sports concept fluctuates and weakens, Huayang Racing falls nearly 10%

According to the Zhitong Finance APP, DEXPO disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 553 million yuan, a year-on-year decrease of 6.21%; net profit attributable to the parent company was 56.93 million yuan, a year-on-year decrease of 30.74%; net profit excluding non-recurring items was 61.4 million yuan, a year-on-year decrease of 33.99%; basic earnings per share were 0.08 yuan. The company plans to distribute a cash dividend of 0.60 yuan (tax included) for every 10 shares

DEXPO released its semi-annual performance report, with a net profit attributable to shareholders of 56.93 million yuan, a year-on-year decrease of 30.74%

According to the Qichacha APP, recently, Changxin Exhibition Co., Ltd. of the Yangtze River Delta Integration Demonstration Zone was established with a registered capital of 20 million yuan. Its business scope includes: conference and exhibition services, business agency services; organizing cultural and artistic exchange activities; sports event planning, etc. Qichacha's equity penetration shows that the company is jointly held by Changxin Urban Operation Management Co., Ltd. of the Yangtze River Delta Integration Demonstration Zone and DEXPO

DEXPO and others established the Changxin Exhibition Company in the Yangtze River Delta Integration Demonstration Zone

On August 20th, DEXPO announced that the company held the 12th meeting of the 11th Board of Directors on the same day, where it reviewed and approved the proposal on the appointment of the company's vice president, appointing Li Li as the vice president of the company, with a term starting from the approval date of this board meeting until the end of the 11th Board of Directors

DEXPO: Appointed Li Li as the company's vice president

According to the Zhitong Finance APP, DEXPO issued a risk warning announcement stating that the company has noticed a recent high level of market attention regarding the concept of "stablecoins." After internal review, the company confirmed that it has not engaged in any "stablecoin" related business. Furthermore, no other media reports or market rumors that could significantly impact the company's stock trading price or involve hot concept matters have been identified at this time

DEXPO: The company has not yet engaged in any "stablecoin" related business

DEXPO announced that it will dispose of no more than 800 million yuan of existing financial assets to actively and prudently adjust its asset structure. This move is carried out under the premise of ensuring that investment risks are controllable and do not affect the normal operation of the company, with an authorization period of 12 months. As of May 31, 2025, the total market value of financial assets held by the company and its subsidiaries is approximately 2.267 billion yuan

DEXPO plans to dispose of no more than 800 million yuan of existing financial assets

According to the Zhitong Finance APP, DEXPO released its first-quarter report for 2025, reporting an operating income of 232 million yuan in the first quarter, a year-on-year increase of 30.98%; the net loss attributable to shareholders of the listed company was 24.5899 million yuan, with losses widening; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.0387 million yuan, with losses narrowing; the basic loss per share was 0.03 yuan/share

DEXPO released its first-quarter performance, with a net loss attributable to the parent company of 24.5899 million yuan, an expanded loss

Chen Xiaohong, Chairman of DEXPO, stated at the performance briefing that the company has exceeded its performance commitment targets and will focus on high-quality development in the future. In 2024, the company's operating revenue is expected to reach 1.643 billion yuan, a year-on-year increase of 15.58%; the net profit attributable to the parent company is expected to be 307 million yuan, a year-on-year increase of 11.44%. The voluntary performance commitment target for the net profit attributable to the parent company after deducting non-recurring gains and losses is not less than 133.6 million yuan, with an actual completion of 205 million yuan

Exhibition industry leader speaks out: Exceeded targets

DEXPO released its 2024 annual report, with operating revenue of 1.643 billion yuan, a year-on-year increase of 15.58%; net profit attributable to shareholders was 307 million yuan, a year-on-year increase of 11.44%. The net profit after deducting non-recurring gains and losses was 226 million yuan, a year-on-year increase of 2.06%. The basic earnings per share were 0.49 yuan, and it plans to distribute a cash dividend of 2.20 yuan (including tax) for every 10 shares to all shareholders

DEXPO released its 2024 annual performance, with a net profit attributable to shareholders of 307 million yuan, an increase of 11.44%

DEXPO(600826.SH)